Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| ClÃnica Dr. Miguel Quesada | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The objective of this study is to evaluate the effect of the combination of a combination of plant extracts (BSL_EP026) on blood and urine uricemia levels in individuals with levels at the limit of the values considered normal or moderately high.
Hyperuricemia is an abnormally high level of uric acid in the blood, resulted because of an increased production of uric acid, decreased excretion of uric acid, or both. This can cause gout and nephrolithiasis, and it has also been related to metabolic syndrome, diabetes mellitus, cardiovascular disease and chronic kidney disease.
Some plant extracts have diuretic activity that could contribute to improve uric acid excretion. This effect would lead to a decrease in uric acid plasma levels and, secondarily, to an action on its metabolic pathway of endogenous biogeneration.
On the other hand, uric acid has a double reabsorption-elimination step in the renal tubules and the flavonoids of both extracts impede the processes of renal resorption promoting urinary elimination, in addition to increase the pH of the urine (higher than pH 5.8), which favors the non-precipitation or formation of urate stones.
Finally, the routine (present in the used extracts) inhibit the uric acid formation pathway from purines, which would act synergistically.
In this project, the effect of the intake of a combination plant extracts on uricemia levels will be studied.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Combination of Plant Extracts (BSL_EP026) | Experimental | Volunteers will take 1 capsule twice daily with the combination of the plant extracts (BSL_EP026). |
|
| Control | Placebo Comparator | Volunteers will take 1 capsule twice daily with maltodextrin. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Combination of Plant Extracts (BSL_EP026) | Combination Product | Each participant will consume 2 capsules daily, in the morning and in the evening. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Uric acid | Uric acid in plasma | 2 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Uric acid in urine | Uric acid in morning spot urine | 2 weeks |
| pH of urine | pH in morning spot urine | 2 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Miguel Quesada, MD, PhD | ClÃnica Dr. Quesada | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Biosearch Life | Granada | Andalusia | 18004 | Spain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D033461 | Hyperuricemia |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Control | Combination Product | Each participant will consume 2 capsules daily, in the morning and in the evening. |
|
|
| Blood pressure | Systolic and diastolic pressure during the study | 2 weeks |
| Fractional clearance of urate (FCU) | Renal clearance of urate/Renal clearance of creatinine | 2 weeks |